Source: Annual Congress 2011 - Tuberculosis epidemiology and public health
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Jain, N. Jain, M. Sharma, R. Aurangabadwalla, N. Joshi, J. Akanksha (Jaipur, India). To study outcome of directly observered treatment shortcourse (DOTS) category I and category II relapses when put on re-treatment regimen (Cat-II DOTS). Eur Respir J 2011; 38: Suppl. 55, 2645

Member's Comments

No comment yet.

Related content which might interest you: Drug resistance pattern of directly observed treatment shortcourse (DOTS) category-II relapse patients Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011 Treatment outcome and one year follow-up status of patients treated under DOTS category II Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 DOT versus self administration in TB treatment in pilot area of sector 4, Bucharest- 3 years early re-treatment analysis Source: Eur Respir J 2004; 24: Suppl. 48, 362s Year: 2004 Outcome in DOTS category II patients by strengthening the regimen with daily levofloxacin Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004 Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Tuberculosis: follow-up of treatment without directed observed therapy (DOT) in a sanitary area Source: Eur Respir J 2004; 24: Suppl. 48, 652s Year: 2004 Outcomes of DOTS and DOTS Plus regimens implementing among patients with pulmonary tuberculosis relapses Source: Eur Respir J 2002; 20: Suppl. 38, 369s Year: 2002 Tuberculosis (TB) relapse rate among patients treated with moxifloxacin (m) or ethambutol (E) in the intensive phase of therapy Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Short 12-month regimen with intravenouse linezolid for MDR-TB:  treatment outcomes and first follow up results. Source: International Congress 2018 – New developments in tuberculosis Year: 2018 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Impact of drug resistance among new cases on outcome of DOTS category I Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 DOTS PLUS versus non DOTS PLUS outcomes in MDRTB patients Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012